RxDoctor Payments Data

Kerri Bally, MD

Critical Care Medicine · Gadsden, ALNPI 1245606805

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by GSK at 41.8% of the total. 2025 is the largest year on record at $974, 5.2 times the $186 reported in 2022.

$2,420in general payments, 2019–2025

Across 122 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$384
  • Sanofi$254
  • Amgen$181
  • Insmed, Inc.$126
  • Regeneron Healthcare Solutions, Inc.$114
  • plus $349 from 11 others

What the payments were for

  • Food & beverage$2,40499%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,420 in reported general payments places this provider in the 75th percentile of 73 critical care medicine providers in Alabama.

See all critical care medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$89,249
Medicare patients
301
Services billed
683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter389$277,402
OfevNintedanib Esylate21$275,457
Breztri AerosphereBudesonide/Glycopyr/Formoterol127$93,602
Spiriva RespimatTiotropium Bromide44$22,045
Breo ElliptaFluticasone/Vilanterol34$15,276
Albuterol Sulfate HfaAlbuterol Sulfate385$11,187
DuleraMometasone/Formoterol33$10,033
Incruse ElliptaUmeclidinium Bromide22$8,129
SymbicortBudesonide/Formoterol Fumarate33$7,971
Varenicline Tartrate14$4,672
Prednisone83$3,804
BreynaBudesonide/Formoterol Fumarate20$3,530
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$3,417
Montelukast Sodium165$1,744
Ventolin HfaAlbuterol Sulfate27$1,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$1,011$300,807445 claims
Boehringer IngelheimOfev, Spiriva Respimat$22$297,50265 claims
AstraZenecaBreztri Aerosphere, Symbicort$384$101,572160 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 73 critical care medicine providers in Alabama.

Other critical care medicine in Gadsden

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →